GSA Capital Partners LLP Reduces Stock Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV)

GSA Capital Partners LLP cut its stake in shares of Verve Therapeutics, Inc. (NASDAQ:VERV) by 82.3% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 36,102 shares of the company’s stock after selling 167,575 shares during the period. GSA Capital Partners LLP’s holdings in Verve Therapeutics were worth $175,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of VERV. Vanguard Group Inc. lifted its position in shares of Verve Therapeutics by 15.7% during the first quarter. Vanguard Group Inc. now owns 6,331,312 shares of the company’s stock worth $84,080,000 after purchasing an additional 859,382 shares in the last quarter. Novo Holdings A S lifted its holdings in Verve Therapeutics by 20.0% in the 2nd quarter. Novo Holdings A S now owns 2,400,000 shares of the company’s stock worth $11,712,000 after buying an additional 400,000 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Verve Therapeutics by 138.1% during the second quarter. Renaissance Technologies LLC now owns 474,500 shares of the company’s stock valued at $2,316,000 after acquiring an additional 275,173 shares in the last quarter. Cubist Systematic Strategies LLC increased its position in shares of Verve Therapeutics by 245.5% during the second quarter. Cubist Systematic Strategies LLC now owns 395,699 shares of the company’s stock worth $1,931,000 after acquiring an additional 281,173 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in shares of Verve Therapeutics by 22.2% in the second quarter. Bank of New York Mellon Corp now owns 274,873 shares of the company’s stock worth $1,341,000 after acquiring an additional 49,922 shares in the last quarter. Hedge funds and other institutional investors own 97.11% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on VERV shares. HC Wainwright dropped their price objective on Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Royal Bank of Canada cut their price target on shares of Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Finally, Canaccord Genuity Group raised their price objective on shares of Verve Therapeutics from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th.

Verve Therapeutics Price Performance

Verve Therapeutics stock opened at $4.85 on Monday. Verve Therapeutics, Inc. has a 12 month low of $4.30 and a 12 month high of $19.34. The company has a fifty day moving average price of $5.35 and a two-hundred day moving average price of $5.61. The company has a market cap of $410.60 million, a PE ratio of -1.97 and a beta of 1.75.

Verve Therapeutics (NASDAQ:VERV) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.70) by $0.11. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. The business had revenue of $6.87 million during the quarter, compared to analyst estimates of $2.75 million. During the same period in the previous year, the business posted ($0.72) EPS. The company’s quarterly revenue was up 120.2% on a year-over-year basis. Equities research analysts anticipate that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current year.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.